Clinical Outcomes of Topical Bevacizumab for the Treatment of Corneal Neovascularization.
| Autor: | Jamaludin MI; Ophthalmology, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, MYS., Wan Abdul Halim WH; Ophthalmology, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, MYS., Cheng TC; Ophthalmology, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, MYS. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2024 May 02; Vol. 16 (5), pp. e59548. Date of Electronic Publication: 2024 May 02 (Print Publication: 2024). |
| DOI: | 10.7759/cureus.59548 |
| Abstrakt: | Background and objective In corneal neovascularization, the peri-corneal vascular structure grows into a normally avascular cornea. This is due to an imbalance between the angiogenic and anti-angiogenic factors that sustain corneal transparency. There are various etiologies of this condition, and they can be divided into infective or non-infective causes, such as inflammation, trauma, or surgical causes. Corneal neovascularization has been shown to improve with the current treatments using steroids and anti-vascular endothelial growth factors. This study aimed to evaluate the effectiveness of topical bevacizumab as an anti-angiogenic agent in patients with corneal neovascularization. Methods This retrospective study included patients who suffered corneal neovascularization of various etiologies and completed six months of topical bevacizumab therapy between 2020 and 2022 at the Universiti Kebangsaan Malaysia Medical Centre. Results A total of 16 patients received treatment with topical bevacizumab over the three-year study period. Based on specified inclusion and exclusion criteria, 12 patients were eligible for inclusion in this study. Eight patients (66%) showed improvement in terms of either 'clock hours' of improvement, morphology, or regression of corneal neovascularization. All infective causes of corneal neovascularization showed improvement on completion of bevacizumab compared to other causes. Conclusion Topical bevacizumab can be one of the treatment choices for corneal neovascularization. As the outcome varies depending on the severity and chronicity of the condition, the attending ophthalmologist should treat each case differently. Although topical bevacizumab is more effective in mild and moderate cases, the indications for its use in chronic cases remain debatable as the results are unfavorable in such cases. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2024, Jamaludin et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|